The VIOXX in prostate cancer prevention study: Cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups

Current Medical Research and Opinion

Volumn 23, Issue 9, 2007, Pages 2063-2070

  Van Adelsberg, Janet ^a   Gann, Peter ^b   Ko, Amy T ^a   Damber, Jan Erik ^c   Logothetis, Christopher ^d   Marberger, Michael ^e   Schmitz Drager, Bernd J ^f   Tubaro, Andrea ^g   Harms, Celia J ^a   Roehrborn, Claus ^h  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c Sahlgrenska Sjukhuset   (Sweden)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF VIENNA   (Austria)

^f Euromed Clinic   (Germany)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Cardiovascular; Prostate cancer; Rofecoxib; Safety

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; HEPARIN; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PROTON PUMP INHIBITOR; ROFECOXIB; SUCRALFATE; TICLOPIDINE; WARFARIN; LACTONE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONE;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BRAIN ISCHEMIA; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; HEART FAILURE; HEART HEMODYNAMICS; HEART INFARCTION; HUMAN; HYPERTENSION; LUNG EDEMA; LUNG EMBOLISM; MALE; MULTICENTER STUDY; PERIPHERAL VASCULAR DISEASE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STROKE; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; BLOOD; MIDDLE AGED; PROSTATE TUMOR; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; HUMANS; LACTONES; MALE; MIDDLE AGED; PLACEBOS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SULFONES; TREATMENT OUTCOME;

EID: 36048954173     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X219526     Document Type: Article

References (18)

1. Ries LAG, Eisner MP, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2002. Bethesda, MD: National Cancer Institute, 2005
2. Lau CK, Black WC, Belley M, et al. From indomethacin to a selective COX-2 inhibitor: development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors. In: Honn KV, Marnett LI, et al., eds. Eicosanoids and other Bioactive Lipids in Cancer Inflammation and Radiation Injury 3. New York: Plenum Press, 1997:73-8
3. Di Lorenzo G, De Placido S, Autorino R, et al. Expression of biomarkers modulating prostate cancer progression: implications in the treatment of the disease. Prostate Cancer Prostatic Dis 2005;8:54-9
4. Liu XH, Kirschenbaum A, Yao S, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol 2000;164:820-5
5. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000;60:4629-37
6. Gupta S, Srivastava M, Ahmad N, et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000;42:73-8
7. Roberts RO, Jacobson DJ, Girman CJ, et al. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002;77:219-25
8. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102
9. Merck Research Laboratories. VIOXX™ (Rofecoxib Tablets and Oral Suspension) - Background briefing information for the food and drug administration joint meeting with the arthritis advisory council and the drug safety and risk management advisory committee. February 16-18, 2005. Accessed on September 29, 2005 at http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005- 4090B1_02_MERCK-Vioxx.pdf
10. Baron JA, Sandler RS, Bresalier RS, et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006;131:1674-82
11. Smith SC, Jr., Blair SN, Bonow RO, et al. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 2001;38:1581-3
12. Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol 1998;93: 2037-46
13. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106
14. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352: 1071-80
15. Jenkins JK, Seligman PJ. Analysis and recommendations for Agency action regarding nonsteroidal anti-inflammatory drugs and cardiovascular risk. http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf.1-19. 4-6-2005
16. EMEA. European Medicines Agency concludes action on COX-2 inhibitors. London, Doc Ref EMEA/2077662005 2005;http://www.emea.eu.int/pdfs/human/press/pr/ 20776605en.pdf Accessed 3 February 2006
17. Kearney PM, Baigent C, Godwin J, et al. Do selective cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J 2006;332:1302-8
18. Gertz BJ, Krupa D, Bolognese JA, et al. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal antiinflammatory agents. Curr Med Res Opin 2002;18:82-91